Maxigen Biotech Inc. (TPE:1783)
43.95
+0.35 (0.80%)
At close: Mar 27, 2026
Maxigen Biotech Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 576.19 | 639.05 | 431.08 | 790.95 | 513.31 |
Short-Term Investments | 301.5 | - | - | 8.82 | 13.84 |
Cash & Short-Term Investments | 877.69 | 639.05 | 431.08 | 799.76 | 527.15 |
Cash Growth | 37.34% | 48.24% | -46.10% | 51.72% | 151.31% |
Accounts Receivable | 132.19 | 103.91 | 88.31 | 98.86 | 109.95 |
Other Receivables | - | - | 8.75 | 1.42 | 4.76 |
Receivables | 132.19 | 103.91 | 97.06 | 100.27 | 114.71 |
Inventory | 99.19 | 75.76 | 85.32 | 75.41 | 80.63 |
Prepaid Expenses | 11.97 | 9.82 | 4.52 | 15.41 | 47.78 |
Other Current Assets | 0.43 | 1.79 | 1.58 | 2.39 | 13.29 |
Total Current Assets | 1,121 | 830.33 | 619.56 | 993.25 | 783.55 |
Property, Plant & Equipment | 442.83 | 430.36 | 424.18 | 434.62 | 465.45 |
Long-Term Investments | 279.68 | 311.31 | 432.8 | - | - |
Other Intangible Assets | 0.73 | 0.13 | 0.49 | 1.16 | 1.83 |
Long-Term Deferred Tax Assets | 1.13 | 2.55 | 5.83 | 3.19 | 0.38 |
Other Long-Term Assets | 47.31 | 7.81 | 10.13 | 15.5 | 13.97 |
Total Assets | 1,893 | 1,582 | 1,493 | 1,448 | 1,265 |
Accounts Payable | 88.22 | 49.98 | 17.17 | 35.94 | 40.15 |
Accrued Expenses | - | 72.07 | 64.63 | 55.35 | 40.35 |
Short-Term Debt | 100 | - | - | - | - |
Current Portion of Leases | - | - | - | - | 2.36 |
Current Income Taxes Payable | 29.61 | 25.52 | 24.47 | 27.17 | 9.28 |
Current Unearned Revenue | 15.1 | 22.93 | 1.34 | 4.25 | 11.13 |
Other Current Liabilities | 116.18 | 35.37 | 23.78 | 28.79 | 12.8 |
Total Current Liabilities | 349.11 | 205.87 | 131.37 | 151.5 | 116.07 |
Long-Term Leases | - | - | - | - | 7.28 |
Long-Term Deferred Tax Liabilities | 1.18 | 0.93 | 0.49 | 0.55 | - |
Other Long-Term Liabilities | 5.26 | 0.56 | 0.02 | 0.02 | 0.12 |
Total Liabilities | 355.54 | 207.36 | 131.88 | 152.07 | 123.47 |
Common Stock | 896.8 | 891.63 | 889.34 | 846.99 | 769.99 |
Additional Paid-In Capital | 331.29 | 326.93 | 296.1 | 281.9 | 264.39 |
Retained Earnings | 534.5 | 344.12 | 244.46 | 169.8 | 110.3 |
Comprehensive Income & Other | -225 | -187.56 | -68.79 | -3.04 | -2.96 |
Total Common Equity | 1,538 | 1,375 | 1,361 | 1,296 | 1,142 |
Shareholders' Equity | 1,538 | 1,375 | 1,361 | 1,296 | 1,142 |
Total Liabilities & Equity | 1,893 | 1,582 | 1,493 | 1,448 | 1,265 |
Total Debt | 100 | - | - | - | 9.64 |
Net Cash (Debt) | 777.69 | 639.05 | 431.08 | 799.76 | 517.51 |
Net Cash Growth | 21.69% | 48.24% | -46.10% | 54.54% | 161.86% |
Net Cash Per Share | 8.62 | 7.12 | 4.82 | 8.95 | 6.12 |
Filing Date Shares Outstanding | 89.49 | 89.16 | 88.93 | 88.93 | 88.93 |
Total Common Shares Outstanding | 89.49 | 89.16 | 88.93 | 88.93 | 88.93 |
Working Capital | 772.36 | 624.47 | 488.19 | 841.75 | 667.49 |
Book Value Per Share | 17.18 | 15.42 | 15.30 | 14.57 | 12.84 |
Tangible Book Value | 1,537 | 1,375 | 1,361 | 1,294 | 1,140 |
Tangible Book Value Per Share | 17.17 | 15.42 | 15.30 | 14.56 | 12.82 |
Land | - | 133.23 | 133.23 | 133.23 | 133.23 |
Buildings | - | 310.48 | 307.74 | 303.11 | 302.48 |
Machinery | - | 181.24 | 160.52 | 149.88 | 162 |
Construction In Progress | - | 20.08 | 17.67 | 21.6 | 18.79 |
Leasehold Improvements | - | 13.43 | 18.91 | 18.91 | 23.7 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.